Jazz Pharmaceuticals Gets Development Rights to Orexin-2 Receptor Agonist with Treatment Potential for Narcolepsy, IH, and More
Jazz Pharmaceuticals has acquired development and commercialization rights in the United States for Sumitomo's investigational DSP-0187.